Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. METHODS: We randomly assigned 16,492 patients with type 2 diabetes who had a history of, or were at risk for, cardiovascular events to receive saxagliptin or placebo and followed them for a median of 2.1 years. Physicians were permitted to adjust other medications, including antihyperglycemic agents. The primary end point was a composite of cardiovascular death, myocardial infarction, or ischemic stroke. RESULTS: A primary end-point event occurred in 613 patients in the saxagliptin group and in 609 patients in the placebo group (7.3% and 7.2%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio with saxagliptin, 1.00; 95% confidence interval [CI], 0.89 to 1.12; P=0.99 for superiority; P<0.001 for noninferiority); the results were similar in the "on-treatment" analysis (hazard ratio, 1.03; 95% CI, 0.91 to 1.17). The major secondary end point of a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, coronary revascularization, or heart failure occurred in 1059 patients in the saxagliptin group and in 1034 patients in the placebo group (12.8% and 12.4%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio, 1.02; 95% CI, 0.94 to 1.11; P=0.66). More patients in the saxagliptin group than in the placebo group were hospitalized for heart failure (3.5% vs. 2.8%; hazard ratio, 1.27; 95% CI, 1.07 to 1.51; P=0.007). Rates of adjudicated cases of acute and chronic pancreatitis were similar in the two groups (acute pancreatitis, 0.3% in the saxagliptin group and 0.2% in the placebo group; chronic pancreatitis, <0.1% and 0.1% in the two groups, respectively). CONCLUSIONS: DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes. (Funded by AstraZeneca and Bristol-Myers Squibb; SAVOR-TIMI 53 ClinicalTrials.gov number, NCT01107886.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Trials of HF outcomes with dapagliflozin and empagliflozin, enrolling up to 50% of participants with type 2 diabetes, report reduction in cardiovascular death and improvement of HF among patients with HF with reduced ejection fraction and HF with preserved ejection fraction, respectively, independent of diabetes status, compared with placebo.66–69,88”
From Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review (2025) · cites this paper as [69]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In 4 trials to date, the DPP4 inhibitors have been shown to be neutral in terms of cardiovascular outcomes.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [186]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of SAVOR-TIMI 53 (NCT01107886) and EXAMINE (NCT00968708) were recently released and showed no increased risk of cardiovascular events with the DPP-4 inhibitors saxagliptin96 and alogliptin97, respectively.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Not all DPP4 inhibitors are associated with higher rates of HF (Table 8).16 -24,184-186”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [19]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Self-citationThe Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Cited by
Items 1,001–1,020 of 1,020
Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Solini, A., Tricò, D., & Del Prato, S. (2023) · Diabetologia · doi:10.1007/s00125-023-05973-w · Cited by 32
Chalmer, T., Almdal, T. P., Vilsbøll, T., & Knop, F. K. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.975205 · Cited by 31
“Moreover, two long-term placebo-controlled trials studying effects of two DDP-4 inhibitors, saxagliptin [52] and alogliptin [53] for a total of 2 and 4 years, respectively, with a total of ~ 20,000 patients, showed no signals of increased rates of pancreatic cancer or pancreatitis.”
BackgroundKarhunen, V., Daghlas, I., Zuber, V., Vujkovic, M., Olsen, A. K., Knudsen, L. B., Haynes, W. G., Howson, J. M. M., & Gill, D. (2021) · Diabetologia · doi:10.1007/s00125-021-05564-7 · Cited by 28
Hyperglycemia management in patients with posttransplantation diabetes
Galindo, R. J., Fried, M., Breen, T., & Tamler, R. (2016) · Endocrine Practice · doi:10.4158/ep151039.ra · Cited by 25
Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors
Tomkin, G. H. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i5.636 · Cited by 24
Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Bahtiyar, G., Pujals-Kury, J., & Sacerdote, A. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1043-z · Cited by 24
Safety and effectiveness of metformin in patients with reduced renal function: a systematic review
Orloff, J., Min, J. Y., Mushlin, A., & Flory, J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14440 · Cited by 24
Cardiovascular biomarkers in clinical studies of type 2 diabetes
Baldassarre, M. P. A., Andersen, A., Consoli, A., Knop, F. K., & Vilsbøll, T. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13247 · Cited by 22
Peng, H., Want, L. L., & Aroda, V. R. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0728-4 · Cited by 20
Petrie (2016) · doi:10.1097/hjh.0000000000000890 · Cited by 20
Kitada, M., Hirai, T., & Koya, D. (2020) · Diabetology International · doi:10.1007/s13340-020-00444-8 · Cited by 19
Nauck, M. A., Meier, J. J., & Schmidt, W. E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12981 · Cited by 19
Scheen, A. J. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.009 · Cited by 18
Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists
Reed, J., Kanamarlapudi, V., & Bain, S. (2018) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000147 · Cited by 16
Kim, C. H., Hwang, I.-C., Choi, H.-M., Ahn, C. H., Yoon, Y. E., & Cho, G.-Y. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.06.027 · Cited by 16
“Whereas dipeptidyl peptidase-4 inhibitors (DPP4i) have failed to show bene�ts in cardiovascular and renal outcomes [ 1, 2 ], sodium glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated robust bene�ts in terms of cardiovascular outcomes in patients with type 2 diabetes, which were mainly…”
Cardiovascular events in individuals treated with sulfonylureas or dipeptidyl peptidase 4 inhibitors
Turchin, A., Petito, L. C., Hegermiller, E., Carnahan, R., DeVries, A., Goel, S., Lansang, M. C., McDonnell, M. E., Nair, V., Priest, E., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.23067 · Cited by 14
Small, A. M., Yang, T.-Y., Itoh, S., Thériault, S., Dufresne, L., Kurosawa, R., Komuro, I., Matsuda, K., Vy, H. M. T., Farber-Eger, E. H., et al. (2026) · Nature Genetics · doi:10.1038/s41588-025-02417-6 · Cited by 18
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Sanon, V., Patel, S., Sanon, S., Rodriguez, R., Pham, S., & Chilton, R. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s97619 · Cited by 6
Korytkowski, M. T., Karslioglu French, E., Brooks, M., DeAlmeida, D., Kanter, J., Lombardero, M., Magaji, V., Orchard, T., & Siminerio, L. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000206 · Cited by 6
“10–12 17 18 In fact, the DPP-IV-I, saxagliptin, was associated with an increase in risk of hospitalization for congestive heart failure (CHF) and hypoglycemia.(11) Whether this was due to the study medication or an epiphenomenon of the study design is not clear.”
Background
Metadata
- Authors
- Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., Cavender, M. A., Udell, J. A., Desai, N. R., Mosenzon, O., McGuire, D. K., Ray, K. K., Leiter, L. A., & Raz, I.
- Affiliations
- Brigham and Women's Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- AstraZeneca (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Hadassah Medical Center (IL)
- St George's, University of London (GB)
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-03
- Volume
- 369
- Issue
- 14
- Pages
- 1317-1326
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2064130493
- Cited by
- 3,470
- References
- 38
- Citations by year
- 2026: 82 · 2025: 137 · 2024: 129 · 2023: 157 · 2022: 182 · 2021: 233 · 2020: 322 · 2019: 324 · 2018: 365 · 2017: 392 · 2016: 422 · 2015: 337 · 2014: 320 · 2013: 57
- FWCI
- 297.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion)
- Hispana (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Griffith Research Online (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- saxagliptin, type 2 diabetes, DPP-4 inhibitors, cardiovascular safety, cardiovascular outcomes, myocardial infarction, ischemic stroke, cardiovascular mortality, heart failure hospitalization, pancreatitis, non-inferiority, antidiabetic drugs, cardiovascular risk stratification, glycemic control
- MeSH terms
- Adamantane, Aged, Aged, 80 and over, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Dipeptides, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Pancreatitis, Kaplan-Meier Estimate, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.